{"id":"W4283376400","doi":"10.1097/01.hs9.0000846460.44039.3d","title":"P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre; University of Calgary; Institute of Cancer Research","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Cytokine release syndrome; Adverse effect; Common Terminology Criteria for Adverse Events; Minimal residual disease; Oncology; Transplantation; Immunology; Gastroenterology; Immunotherapy; Cancer; Chimeric antigen receptor; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00802533,0.001184139,0.001729428,0.0009431352,0.0003937852,0.001504602,0.001600269,0.0009746328,0.004866845],"category_scores_gemma":[0.004377953,0.0004154659,0.001626679,0.001416604,0.0002986433,0.001104155,0.0007467182,0.00175285,0.001951438],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001232659,"about_ca_system_score_gemma":0.002246551,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002141385,"about_ca_topic_score_gemma":0.005184676,"domain_scores_codex":[0.9974189,0.001091991,0.0002431433,0.0002269269,0.000795677,0.0002233806],"domain_scores_gemma":[0.9959239,0.00101091,0.001393719,0.0002514448,0.0009396348,0.0004804843],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.09943487,0.004323956,0.05873852,0.007001716,0.008371298,0.0009169427,0.0003181314,0.005111548,0.05074482,0.000424381,0.1261749,0.638439],"study_design_scores_gemma":[0.07389325,0.09257201,0.4377045,0.001280289,0.02785658,0.004642494,0.0002153394,0.003173204,0.0285672,0.0008945197,0.3289639,0.0002367216],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5736948,0.1485694,0.01365348,0.01143675,0.002435618,0.007497604,0.1969294,0.001697573,0.0440854],"genre_scores_gemma":[0.6335092,0.03749741,0.01635922,0.01250832,0.001891211,0.004408846,0.2821842,0.0005670951,0.01107442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00802533,"threshold_uncertainty_score":0.0424425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02427076217442896,"score_gpt":0.291956138476212,"score_spread":0.2676853763017831,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}